Ami Fadia Reiterates Buy on Jazz Pharmaceuticals, Maintains $292 Price Target Following Actio Biosciences Acquisition
Tip Ranks·
- Needham analyst Ami Fadia reaffirmed a buy rating on Jazz Pharmaceuticals with a price target of $ 292.00 following the strategic acquisition of Actio Biosciences and its primary asset ABS-1230.
- The acquisition expands the company's rare epilepsy portfolio with a KCNT1 ion channel inhibitor currently undergoing a Phase 1b/2a clinical study for KCNT1 related epilepsy.
- The transaction involves an upfront payment of $ 820 million plus milestones, which is deemed strategically sound given the asset's high pricing potential and favorable regulatory framework prospects.